The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | The MMyeRisk project: developing minimally invasive methods for staging MGUS and smoldering myeloma
Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, shares insights into the MMyeRisk project, an international collaboration with the aim of developing minimally invasive methods for staging patients with monoclonal gammopathy of unknown significance (MGUS) and smoldering myeloma (SMM). The research focuses on utilizing circulating tumor cells and immune biomarkers for improved prediction of disease progression and for the development of individualized early intervention strategies. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
